HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study.

Abstract
Linezolid, the first oxazolidinone, is active against gram-positive bacteria, including multidrug-resistant strains. This multinational, randomized, double-blind, controlled trial compared the efficacy, safety, and tolerability of linezolid with vancomycin in the treatment of nosocomial pneumonia. A total of 203 patients received intravenous linezolid, 600 mg twice daily, plus aztreonam, and 193 patients received vancomycin, 1 g intravenously twice daily, plus aztreonam for 7-21 days. Clinical and microbiological outcomes were evaluated at test of cure 12-28 days after treatment. Clinical cure rates (71 [66.4%] of 107 for linezolid vs. 62 [68.1%] of 91 for vancomycin) and microbiological success rates (36 [67.9%] of 53 vs. 28 [71.8%] of 39, respectively) for evaluable patients were equivalent between treatment groups. Eradication rates of methicillin-resistant Staphylococcus aureus and safety evaluations were similar between treatment groups. Resistance to either treatment was not detected. Linezolid is a well-tolerated, effective treatment for adults with gram-positive nosocomial pneumonia.
AuthorsE Rubinstein, S Cammarata, T Oliphant, R Wunderink, Linezolid Nosocomial Pneumonia Study Group
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 32 Issue 3 Pg. 402-12 (Feb 01 2001) ISSN: 1058-4838 [Print] United States
PMID11170948 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
Chemical References
  • Acetamides
  • Anti-Bacterial Agents
  • Monobactams
  • Oxazolidinones
  • Vancomycin
  • Aztreonam
  • Linezolid
Topics
  • Acetamides (adverse effects, therapeutic use)
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents (adverse effects, therapeutic use)
  • Aztreonam (therapeutic use)
  • Cross Infection (drug therapy)
  • Double-Blind Method
  • Drug Resistance, Microbial
  • Drug Therapy, Combination
  • Gram-Positive Bacteria (drug effects)
  • Hospitalization
  • Humans
  • Linezolid
  • Male
  • Middle Aged
  • Monobactams (therapeutic use)
  • Oxazolidinones (adverse effects, therapeutic use)
  • Pneumonia (drug therapy)
  • Safety
  • Time Factors
  • Treatment Outcome
  • Vancomycin (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: